Screening and primary and secondary interventions for patients at high risk for ovarian cancer

Women's Oncology Review

Volumn 3, Issue 4, 2003, Pages 269-274

  Goldman, Noah A ^a   Restivo, Antonella ^a   Goldberg, Gary L ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; ORAL CONTRACEPTIVE AGENT;

ARTICLE; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; FEMALE; GENE MUTATION; GENETIC COUNSELING; GENETIC SUSCEPTIBILITY; HETEROZYGOTE DETECTION; HIGH RISK POPULATION; HUMAN; INCIDENCE; OVARY CANCER; PRACTICE GUIDELINE; PRIMARY PREVENTION; RISK REDUCTION; SALPINGOOOPHORECTOMY; SECONDARY PREVENTION; SIDE EFFECT; TRANSVAGINAL ECHOGRAPHY;

EID: 0345832168     PISSN: 14733404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. American Cancer Society. American Cancer Society Facts and Figures. Atlanta, GA: American Cancer Society, 2002
2. Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990;250:1684-9
3. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian susceptibility gene BRCA1. Science 1994;266:66-71
4. Lynch HT, Bewra C, Lynch JF. Familial ovarian cancer clinical nuances. Am J Med 1983;81:1073
5. Liede A, Tonin PN, Sun CC, et al. Is hereditary site-specific ovarian cancer a distinct genetic condition? Am J Med Genet 1998;75:55-8
6. Ford D, Easton DF, Bishop DT, et al. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994;343:692-5
7. Struewing JF, Abeliovich D, Peretz T, et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi-Jewish individuals. Nat Genet 1995;11:198-200
8. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700-10
9. Satagopan JM, Boyd J, Kauff ND, et al. Ovarian cancer risk in Ashkenazi-Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res 2002;8:3776-81
10. Brose MS, Rebbeck TR, Calzone KA, et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002;94:1365-72
11. Gotlieb WH, Friedman E, Bar-Sade RB, et al. Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors. J Natl Cancer Inst 1998;90:995-1000
12. Easton DF, Steele L, Fields P, et al. Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet 1997;61:120-8
13. Struewing JP, Hartge F, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8
14. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56:265-71
15. Moslehi R, Chu W, Karlan B, et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 2000;66:1259-72
16. Fishman A, Dekel E, Chetrit A, et al. Patients with double primary tumors in the breast and ovary - clinical characteristics and BRCA1-2 mutations status. Gynecol Oncol 2000;79:74-8
17. Menczer J, Chetrit A, Barda G, et al. Frequency of BRCA mutations in primary peritoneal carcinoma in Israeli Jewish women. Gynecol Oncol 2003;88:58-61
18. Tonin P, Moslehi R, Green R, et al. Linkage analysis of 26 Canadian breast and breast-ovarian cancer families. Hum Genet 1995;95:545-50
19. Schubert EL, Lee MK, Mefford HC, et al. BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2. Am J Hum Genet 1997;60:1031-40
20. Zweemer RP, van Diest PJ, Verheijen RH, et al. Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol 2000;76:45-50
21. Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001;195:451-6
22. Eisinger F, Stoppa-Lyonnet D, Longy M, et al. Germ-line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 1996;56:471-4
23. Marcus JN, Watson P, Page DL, et al. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 1996;77:697-709
24. Rubin SC, Benjamin I, Behbakht K, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996;335: 1413-16
25. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. J Am Med Assoc 2000;283:2260-5
26. Zweemer RP, Verheijen RH, Coebergh JW, et al. Survival analysis in familial ovarian cancer: a case-control study. Eur J Obstet Gynecol Reprod Biol 2001;98:219-23
27. Ben David Y, Chetrit A, Hirsh-Yechezkel G, et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 2002;20:463-6
28. Shaw PA, McLaughlin JR, Zweemer RP, et al. Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol 2002;21:407-11
29. Sharan SK, Morimatsu M, Albrecht U, et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking BRCA2. Nature 1997;386:804-10
30. Pierce LJ, Strawderman M, Narod SA, et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 2000;18:3360-9
31. Hilton JL, Geisler JF, Rathe JA, et al. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 2002;94:1396-406
32. Creasman WT, DiSaia PJ. Screening in ovarian cancer. Am J Obstet Gynecol 1991; 165:7-10
33. Karlan BY, Raffel LJ, Crvenkovic G, et al. A multidisciplinary approach to the early detection of ovarian carcinoma: rationale, protocol design and early results. Am J Obstet Gynecol 1993; 169:494-501
34. American Society of Clinical Oncology. Genetic testing for cancer susceptibility. Statement of ASCO adopted on 20 February 1996. J Clin Oncol 1996;14:1730-6 (discussion 1737-40)
35. Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. J Am Med Assoc 1997;277:997-1003
36. Vasen HF, Haites NE, Evans DG, et al. Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group. Eur J Cancer 1998;34:1922-6
37. Franceschi S, Parazzini F, Negri E, et al. Pooled analysis of three European case-control studies of epithelial ovarian cancer. III. Oral contraceptive use. Int J Cancer 1991; 49:61-5
38. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 1992;136:1184-203
39. Narod SA, Sun P, Risch HA. Ovarian cancer, oral contraceptives and BRCA mutations. N Engl J Med 2001;345: 1706-7
40. Modan B, Hartge P, Hirsh-Yechezkel G, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345:235-40
41. Bourne TH, Whitehead MI, Campbell S, et al. Ultrasound screening for familial ovarian cancer. Gynecol Oncol 1991;43:92-7
42. Menon U, Talaat A, Rosenthal AN, et al. Performance of ultrasound as a second-line test to serum CA-125 in ovarian cancer screening. Br J Obstet Gynaecol 2000;107:165-9
43. Parazzini F Braga C, La Vecchia C, et al. Hysterectomy, oophorectomy in premenopause, and risk of breast cancer. Obstet Gynecol 1997;90:453-6
44. Rebbeck TR, Levin AM, Eisen A, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999;91:1475-9
45. Scheuer L, Kauff N, Robson M, et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 2002;20:1260-8
46. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346: 1609-15
47. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-22
48. Hankinson SE, Hunter DJ, Colditz GA, et al. Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. J Am Med Assoc 1993;270:2813-18
49. Narod SA, Sun P, Ghadirian P, et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet 2001;357: 1467-70
50. Schrag D, Kuntz KM, Garber JE, et al. Decision analysis-effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997;336:1465-71
51. van Roosmalen MS, Verhoef LC, Stalmeier PF, et al. Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy. J Clin Oncol 2002;20:2092-100
52. Lu KH, Garber JE, Cramer DW, et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 2000;18:2728-32
53. Colgan TJ, Murphy J, Cole DE, et al. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 2001;25:1283-9
54. Leeper K, Garcia R, Swisher E, et al. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 2002;87:52-6
55. Colgan TJ, Boerner SL, Murphy J, et al. Peritoneal lavage cytology: an assessment of its value during prophylactic oophorectomy. Gynecol Oncol 2002;85:397-403
56. Paley PJ, Swisher EM, Garcia RL, et al. Occult cancer of the fallopian tube in BRCA1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy as surgical prophylaxis. Gynecol Oncol 2001;80:176-80
57. Levine DA, Gemignani ML. Prophylactic surgery in hereditary breast/ovarian cancer syndrome. Oncology (Huntingt) 2003;17:932-41, discussion 946-8, 950-2
58. Kauff ND, Scheuer L, Robson ME, et al. Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with BRCA1 or BRCA2 mutations. Genet Med 2001;3:422-5